logo
OKC's Louisa McCune Animal Welfare Center breaks ground

OKC's Louisa McCune Animal Welfare Center breaks ground

Yahoo28-02-2025

OKLAHOMA CITY (KFOR) – The name of OKC's new animal shelter is the Oklahoma City Louisa McCune Animal Welfare Center. It broke ground on Thursday.
'This original building was built back in 1996 and it's time for an upgrade,' said Councilman Todd Stone, City of Oklahoma City.
LOCAL NEWS: Loving and adoptable pets available this February
McCune spent years advocating for humane living conditions for animals in Oklahoma and around the world. She significantly contributed to the new shelter project before passing away last year.
'I know Louisa is here with us in spirit, and she would absolutely be thrilled,' said Kelly Barnes of the Kirkpatrick Foundation. 'She said, where animals fare well, people fare well.'
The $42 million project is funded through MAPS 4.
'It's designed to improve the care for the animals, but also improve conditions for our staff and our volunteers,' said Stone.
The center will be constructed in two phases. One, building the main shelter and two, rebuilding the 2,800 square foot barn, providing parking and removing the current structure.
The new facility will more than double the number of dog kennels to nearly 550 and increase the number of cat condos to more than 300.
LOCAL NEWS: OKC Zoo welcomes Eastern collared lizards
'It's not just about being prettier and having newer, nicer things,' said Mayor David Holt. 'Sometimes capacity limitations drive decisions about euthanasia that might have not occurred otherwise.'
The new building is scheduled to open in 2026.
'There's a lot that's going to happen at this place, and that's certainly a fulfillment of Louisa's expansive vision for it,' said Holt.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Yahoo

time4 hours ago

  • Yahoo

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Yahoo

time5 hours ago

  • Yahoo

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@ A replay of the webcast will be available on the Company's website at following the conclusion of the event. About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Contact Vaxart Media and Investor Relations: Matt Steinberg FINN Partners IR@ (646) 871-8481 This press release was published by a CLEAR® Verified individual.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store